Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Crinetics Pharmaceuticals — Net loss by Quarter
Crinetics Pharmaceuticals — Net loss ($M) ($M)
Vertex Pharmaceuticals Crinetics Pharmaceuticals — Net loss: -$121M in Q2 2026, up 4.5% from a year earlier.
Latest, Q2 2026
-121
Period ended Jun 30, 2026
Change on a year earlier
+4.5%
-116 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
25
Documents cited below
Where the Q2 2026 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001699813 Crinetics Pharmaceuticals).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Crinetics Pharmaceuticals — Net loss ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -121 | +4.5% | SEC Filing ↗ |
| Q1 2026 | Mar 31, 2026 | -128 | +32.1% | SEC Filing ↗ |
| Q4 2025 | Dec 31, 2025 | -123 | +52.4% | SEC Filing ↗ |
| Q3 2025 | Sep 30, 2025 | -130 | +69.3% | SEC Filing ↗ |
| Q2 2025 | Jun 30, 2025 | -116 | +56.2% | SEC Filing ↗ |
| Q1 2025 | Mar 31, 2025 | -96.8 | +44.6% | SEC Filing ↗ |
| Q4 2024 | Dec 31, 2024 | -80.6 | +34.1% | SEC Filing ↗ |
| Q3 2024 | Sep 30, 2024 | -76.8 | +33.7% | SEC Filing ↗ |
| Q2 2024 | Jun 30, 2024 | -74.1 | +45.3% | SEC Filing ↗ |
| Q1 2024 | Mar 31, 2024 | -66.9 | +45.5% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | -60.1 | +33.6% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | -57.5 | +37.1% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | -51.0 | +20.3% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | -46.0 | +32.8% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | -45.0 | +46.1% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | -41.9 | +50.5% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | -42.4 | +62.4% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | -34.6 | +51.2% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | -30.8 | +42.3% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | -27.9 | +52.0% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | -26.1 | +58.2% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | -22.9 | +31.9% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | -21.6 | +48.7% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | -18.3 | +27.0% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | -16.5 | +32.7% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | -17.4 | +92.5% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | -14.6 | +71.4% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | -14.4 | +90.1% | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | -12.4 | +123.2% | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | -9.02 | +65.2% | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | -8.49 | – | SEC Filing ↗ |
| Q3 2018 | Sep 30, 2018 | -7.59 | – | SEC Filing ↗ |
| Q2 2018 | Jun 30, 2018 | -5.57 | – | SEC Filing ↗ |
| Q1 2018 | Mar 31, 2018 | -5.46 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Crinetics Pharmaceuticals — Net loss ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crinetics-net-inc
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.